Instil Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TIL Nasdaq 2836 instilbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Instil Bio, Inc.

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 15th, 2026 5:00 am
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Mar 27th, 2026 5:00 am
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround - Feb 3rd, 2026 8:20 am
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - Feb 3rd, 2026 8:06 am
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco - Jan 6th, 2026 5:00 am
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 5:00 am
Tumor Infiltrating Lymphocytes Therapy Market Research Report 2025-2030: Market Driven by Active R&D from Iovance Biotherapeutics, Juncell Therapeutics, Biosyngen, and Instil Bio - Oct 21st, 2025 3:34 am
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) - Sep 10th, 2025 5:00 am
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company - Aug 16th, 2025 6:23 am
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 13th, 2025 4:00 am